ReviewJACC. CardioOncology2023
Screening for Coronary Artery Disease in Cancer Survivors:
Review in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 65 citations in OpenAlex.
- A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints.International journal of cancer · 2025Trial
- Review
- Heart Substructure Radiation Dose and Cardiac Outcomes: Contemporary Evidence and Actionable Opportunities: JACC CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2026Review
- Inflammation mediates platinum-based chemotherapy-induced risk of adverse cardiac events in older NSCLC patients: a pilot study.Cardio-oncology (London, England) · 2026Article
- Performance of Traditional Cardiovascular Risk Scores and Objective Optimization in Cancer Survivors.Current oncology (Toronto, Ont.) · 2026Article
- Cancer treatment-related cardiotoxicity, molecular mechanism, challenges, and research trends.Discover oncology · 2026Review
- Prevalence of obstructive coronary artery disease in asymptomatic cancer patients with elevated troponin levels.Cardio-oncology (London, England) · 2026Article
- Coronary artery calcification burden in cancer vs. non-cancer populations: a systematic review and meta-analysis.Cardio-oncology (London, England) · 2026Article
- Identification of drug-related cardiovascular risks: A comprehensive analysis using the FAERS database (2004-2024).PloS one · 2026Article
- Chemotherapy-induced cardiotoxicity in breast cancer: mechanisms, diagnostic advances, and emerging protective strategies.American journal of physiology. Heart and circulatory physiology · 2025Review
- Association Between Cancer Treatment History and Coronary Inflammation.JACC. Advances · 2025Article
- Effects of Exercise on Cardiovascular and Metabolic Responses in Adults and Childhood Cancer Survivors: The Role of NETosis and Low-Grade Inflammation as a Novel Therapeutic Target-A Narrative Review.International journal of molecular sciences · 2025Review
- Radiation- and age-related vascular dysfunction as an early indicator of cardiovascular risk: a long-term study in the ApoECardio-oncology (London, England) · 2025Article
- Timing and combinations of cardiovascular diseases in survivors of childhood, adolescent, and young adulthood cancer.Cardio-oncology (London, England) · 2025Article
- Overlapping risk factors and pathogenic mechanisms in lung cancer and cardiovascular disease.Discover oncology · 2025Review
- Polygenic risk of coronary artery disease for long-term survivors of breast cancer.Journal of the National Cancer Institute · 2025Article
- Accelerated Atherosclerosis in Early-Stage Breast Cancer Following Chemotherapy.JACC. Case reports · 2025Article
- CT-Based Pericardial Composition Change as an Imaging Biomarker for Radiation-Induced Cardiotoxicity.Cancers · 2025Article
- Clonal Hematopoiesis in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- A Comprehensive Review of Radiotherapy-Induced Coronary Artery Disease-Epidemiology, Biological Mechanisms, and Preventive Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) is an important contributor to the cardiovascular burden in cancer survivors. This review identifies features that could help guide decisions about the benefit of screening to assess the risk or presence of subclinical CAD. Screening may be appropriate in selected survivors based on risk factors and inflammatory burden. In cancer survivors who have undergone genetic testing, polygenic risk scores and clonal hematopoiesis markers may become useful CAD risk prediction tools in the future. The type of cancer (especially breast, hematological, gastrointestinal, and genitourinary) and the nature of treatment (radiotherapy, platinum agents, fluorouracil, hormonal therapy, tyrosine kinase inhibitors, endothelial growth factor inhibitors, and immune checkpoint inhibitors) are also important in determining risk. Therapeutic implications of positive screening include lifestyle and atherosclerosis interventions, and in specific instances, revascularization may be indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.